Timberline Investments

At Timberline, we hold no exit strategy—we analyze the market based on long-term expectations rather than temporary trends.

Goodrich, Braxton

Managing Director

8 past transactions

Birdstop

Venture Round in 2023
Birdstop specializes in creating advanced solutions for the inspection and monitoring of remote assets through the use of autonomous drones. The company has developed a platform that automates data collection, allowing users to oversee their assets efficiently and effectively. By employing networked UAVs and ground stations, Birdstop provides real-time insights and data via the Internet, enabling asset owners to identify anomalies and make informed decisions without needing to be physically present. This innovative approach supports industries that rely on offsite physical assets, enhancing operational efficiency and decision-making processes.

Conserv

Series A in 2022
Conserv is a software and sensors company revolutionizing the art conservation industry with its comprehensive platform tailored for conservation professionals. The company specializes in environmental monitoring, a vital aspect of conservation work, and has created a unique wireless monitoring system specifically designed for this purpose. Its mobile application facilitates accurate, real-time data collection, allowing users to easily set up and customize environmental standards based on the specific needs of their art collections. By integrating various conservation tasks into a single solution, Conserv aims to enhance the efficiency and effectiveness of conservation efforts.

Intrommune Therapeutics

Series A in 2021
Intrommune Therapeutics is a clinical-stage biotechnology company focused on developing safe and effective treatments for food allergies. The company’s Oral Mucosal Immunotherapy (OMIT) platform utilizes a specially formulated toothpaste that allows patients to safely expose their immune systems to allergenic proteins while maintaining oral hygiene. The primary product under development, INT301, targets peanut allergy, addressing a significant unmet need in a market with limited treatment options. Currently, only one FDA-approved product for food allergies exists, which requires patients to ingest peanut protein, a method that many find difficult and risky. Intrommune's innovative approach aims to provide a more accessible and manageable solution for patients and their families, reducing the fear associated with food allergies. The company is conducting a Phase 1b study for INT301, with important developmental milestones expected in the coming year.

Mixtroz

Seed Round in 2021
Mixtroz, LLC is a Birmingham, Alabama-based company that specializes in developing a software application aimed at enhancing virtual communication during various gatherings, including networking events, meetings, and weddings. Founded in 2014, Mixtroz addresses the challenge of attendee engagement, particularly in settings where participants may struggle to connect effectively. By employing digital communication and machine learning algorithms, the application facilitates interaction among attendees while simultaneously collecting real-time data for event organizers. This approach allows hosts to form groups based on attendee responses, fostering valuable connections and improving the overall experience for both hosts and participants.

ResBiotic

Seed Round in 2021
ResBiotic is a company that focuses on developing probiotic and pharmabiotic therapies aimed at alleviating neutrophilic inflammation linked to dysbiosis. Founded in 2019 and based in Vestavia Hills, Alabama, ResBiotic specializes in creating anti-inflammatory probiotic products designed to restore a healthy lung microbiome. By targeting the gut-lung axis, these therapies aim to reduce inflammation and help patients manage respiratory illnesses effectively.

Acclinate

Pre Seed Round in 2021
Acclinate is a venture-backed company focused on enhancing representation and diversity in genomic research and clinical trials through its digital health platform. By utilizing machine learning and predictive analytics, Acclinate automates the processes of identifying, educating, engaging, and retaining diverse participants for research studies. This approach not only empowers communities to improve their health outcomes but also helps biopharmaceutical organizations reduce the overall costs associated with drug development. Through sustained engagement and AI-driven insights, Acclinate aims to foster better health practices and outcomes within underrepresented populations.

KAYA Climb

Seed Round in 2020
Kaya Climb is a climber’s app designed to connect users with the gym and local climbing community and find and share beta. It enables climbers to build an ascent pyramid, and review past climbing sessions. The company was founded in 2019 when a crew of climbers and technologists got together to create a platform for the climbing community.

Urgent Care for Children

Series A in 2019
Urgent Care for Children is a healthcare provider specializing in pediatric services for children and infants. Founded in 2017 and based in Birmingham, Alabama, the company operates after-hours urgent care clinics that focus on non-emergency medical needs. Its services include general check-ups, diagnostic testing, laboratory services, sensory evaluations, x-rays, and pharmacy services. Urgent Care for Children aims to offer accessible and comprehensive care for minor illnesses and injuries, ensuring that children receive appropriate treatment without the need for emergency care facilities. In cases of potentially life-threatening conditions, the company advises contacting emergency services or visiting a hospital.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.